Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo.
Pancreatic cancer is highly resistant to the currently available chemotherapeutic agents. Less than 5% of patients diagnosed with this disease could survive beyond 5 years. Thus, there is an urgent need for the development of novel, efficacious drugs that can treat pancreatic cancer. Herein we report the identification of artesunate (ART), a derivative of artemisinin, as a potent and selective antitumor agent against human pancreatic cancer cells in vitro and in vivo. ART exhibits selective cytotoxic activity against Panc-1, BxPC-3 and CFPAC-1 pancreatic cancer cells with IC(50) values that are 2.3- to 24-fold less than that of the normal human hepatic cells (HL-7702). The pan caspase inhibitor zVAD-fmk did not inhibit the cytotoxic activity of ART. Electron microscopy of ART-treated cells revealed severe cytoplasmic swelling and vacuolization, swollen and internally disorganized mitochondria, dilation (but not fragmentation) of the nuclei without chromatin condensation, and cell lysis, yielding a morphotype that is typical of oncosis. The ART-treated cells exhibited a loss of mitochondrial membrane potential (DeltaPsim) and ART-induced cell death was inhibited in the presence of the reactive oxygen species (ROS) scavenger N-acetyl-cysteine (NAC). Importantly, ART produced a dose-dependent tumor regression in an in vivo pancreatic cancer xenografts model. The in vivo antitumor activity of ART was similar to that of gemcitabine. Taken together, our study suggests that ART exhibits antitumor activity against human pancreatic cancer via a novel form of oncosis-like cell death, and that ART should be considered a potential therapeutic candidate for treating pancreatic cancer.
Du
Ji-Hui
JH
Central Laboratory, Nanshan Hospital, Guangdong Medical College, 518052 Shenzhen, Guangdong Province, People's Republic of China.
Zhang
Hou-De
HD
Ma
Zhen-Jian
ZJ
Ji
Kun-Mei
KM
D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis; D037621:Artemisinins / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D000077332:Artesunate; D016923:Cell Death; D045744:Cell Line, Tumor; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000648:ultrastructure; D017382:Reactive Oxygen Species / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D037621:Artemisinins; D017382:Reactive Oxygen Species; D000077332:Artesunate
J Immunol Methods. 1991 Jun 3;139(2):271-9
1710634
Biochem Pharmacol. 2004 Dec 15;68(12):2359-66
15548382
J Cell Mol Med. 2009 Jul;13(7):1358-70
18466355
Neoplasma. 2007;54(1):29-36
17203890
Genes Dev. 2006 Jan 1;20(1):1-15
16391229
PLoS One. 2007 Aug 01;2(8):e693
17668070
Int J Parasitol. 2002 Dec 4;32(13):1655-60
12435450
Microbiol Rev. 1996 Jun;60(2):301-15
8801435
Trends Biochem Sci. 2007 Jan;32(1):37-43
17141506
Biochem Pharmacol. 2009 Aug 1;78(3):273-83
19393226
Expert Opin Investig Drugs. 2006 Nov;15(11):1395-410
17040199
Oncologist. 2006 Apr;11(4):342-57
16614230
Mol Cancer. 2003 Jan 07;2:6
12605713
Int J Oncol. 2001 Apr;18(4):767-73
11251172
Cell Res. 2004 Feb;14(1):81-5
15040894
Anat Histol Embryol. 2002 Aug;31(4):214-23
12196263
Toxicol Pathol. 1997 Jan-Feb;25(1):82-8
9061857
Anticancer Drugs. 2008 Jun;19(5):435-46
18418211
Exp Cell Res. 2000 Apr 10;256(1):42-9
10739650
Drug Saf. 1995 Apr;12(4):264-73
7646825
Mol Pharmacol. 2003 Aug;64(2):382-94
12869643
Clin Cancer Res. 2008 Sep 1;14(17):5519-30
18765544
Am J Pathol. 1995 Jan;146(1):3-15
7856735
Int J Oncol. 2003 Oct;23(4):1231-5
12964009
Cancer Res. 2008 Jun 1;68(11):4347-51
18519695
J Pharm Pharmacol. 2007 Jun;59(6):849-56
17637177
Gastroenterology. 2005 May;128(6):1606-25
15887154
Biochim Biophys Acta. 1998 Aug 10;1366(1-2):177-96
9714796
Arzneimittelforschung. 1996 Feb;46(2):196-200
8720313